Glaukos Co. (NYSE:GKOS) Short Interest Up 5.6% in February

Glaukos Co. (NYSE:GKOS – Get Rating) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 4,720,000 shares, an increase of 5.6% from the February 13th total of 4,470,000 shares. Based on an average daily volume of 398,600 shares, the short-interest ratio is presently 11.8 days. Currently, 10.3% of the company’s shares are short sold.

Glaukos Trading Down 1.9 %

Shares of GKOS traded down $0.96 during mid-day trading on Friday, hitting $48.45. The company’s stock had a trading volume of 158,909 shares, compared to its average volume of 418,182. The company’s 50-day moving average is $48.74 and its 200-day moving average is $49.57. Glaukos has a 52-week low of $33.33 and a 52-week high of $64.49. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.13 and a quick ratio of 5.61.

Glaukos (NYSE:GKOS – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The medical instruments supplier reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.03. Glaukos had a negative net margin of 35.07% and a negative return on equity of 18.51%. The firm had revenue of $71.23 million during the quarter, compared to analysts’ expectations of $67.71 million. As a group, analysts expect that Glaukos will post -2.38 EPS for the current year.

Institutional Investors Weigh In On Glaukos

Several hedge funds have recently modified their holdings of GKOS. Quadrant Capital Group LLC lifted its position in shares of Glaukos by 262.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,011 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 732 shares during the period. Captrust Financial Advisors raised its stake in shares of Glaukos by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 254 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of Glaukos during the 4th quarter worth approximately $112,000. Point72 Middle East FZE bought a new position in shares of Glaukos during the 4th quarter worth approximately $189,000. Finally, AlphaCrest Capital Management LLC bought a new position in shares of Glaukos during the 3rd quarter worth approximately $205,000. Hedge funds and other institutional investors own 92.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $42.00 to $48.00 and gave the stock a “neutral” rating in a research note on Thursday, February 23rd. StockNews.com initiated coverage on shares of Glaukos in a research note on Thursday. They set a “sell” rating for the company. Stephens lowered their price objective on shares of Glaukos from $69.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday, December 28th. Needham & Company LLC lowered their price objective on shares of Glaukos from $58.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, February 23rd. Finally, Citigroup boosted their price objective on shares of Glaukos from $57.00 to $59.00 and gave the company a “buy” rating in a research report on Thursday, February 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $56.67.

About Glaukos

(Get Rating)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.